Literature DB >> 12134269

Role of upper and lower respiratory tract immunity in resistance to Mycoplasma respiratory disease.

Lisa M Hodge1, Jerry W Simecka.   

Abstract

This study determined whether respiratory tract immunization protects against mycoplasma infection and compared preferential immunization of the upper respiratory tract (nasal) with upper and lower respiratory tract (nasal-pulmonary) immunization. Small volumes of inoculum preferentially deposited antigen and induced IgA responses in nasal passages. Larger inoculums deposited antigen in both the upper and lower respiratory tracts, generating corresponding IgA responses. Mice were given nasal or nasal-pulmonary immunizations with Mycoplasma pulmonis antigen alone or with cholera toxin (CT), and resistance to infection was determined. Generation of upper respiratory tract immunity reduced mycoplasma infection at this site, but CT was needed to elicit protective responses. In the lower respiratory tract, nasal-pulmonary immunization was most effective, but nasal immunization did confer some protection from pulmonary infection. In contrast, intraperitoneal immunization resulted in little protection. Thus, respiratory tract immunity plays a major role in resisting mycoplasma infection, and it should be considered during vaccine development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12134269     DOI: 10.1086/341280

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Interferon gamma and interleukin 4 have contrasting effects on immunopathology and the development of protective adaptive immunity against mycoplasma respiratory disease.

Authors:  Sheetal Bodhankar; Xiangle Sun; Matthew D Woolard; Jerry W Simecka
Journal:  J Infect Dis       Date:  2010-07-01       Impact factor: 5.226

2.  Induction of mucosal immunity through systemic immunization: Phantom or reality?

Authors:  Fei Su; Girishchandra B Patel; Songhua Hu; Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

3.  Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis.

Authors:  Girish S Kirimanjeswara; Luis M Agosto; Mary J Kennett; Ottar N Bjornstad; Eric T Harvill
Journal:  J Clin Invest       Date:  2005-11-17       Impact factor: 14.808

4.  Humoral immune responses and protective efficacy of sequential B- and T-cell epitopes of V antigen of Yersinia pestis by intranasal immunization in microparticles.

Authors:  Jayaprakash Babu Uppada; Arif Azam Khan; Ajaz Ahmad Bhat; Ranjana Deshmukh; Donthamsetty Nageswara Rao
Journal:  Med Microbiol Immunol       Date:  2009-09-25       Impact factor: 3.402

Review 5.  Gas-filled microbubbles: Novel mucosal antigen-delivery system for induction of anti-pathogen's immune responses in the gut.

Authors:  Blaise Corthésy; Gilles Bioley
Journal:  Gut Microbes       Date:  2017-05-25

6.  NK cells in gamma-interferon-deficient mice suppress lung innate immunity against Mycoplasma spp.

Authors:  Matthew D Woolard; Dorothy Hudig; Leslie Tabor; James A Ivey; Jerry W Simecka
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

7.  THE MULTIFACETED ROLE OF T CELL-MEDIATED IMMUNITY IN PATHOGENESIS AND RESISTANCE TO MYCOPLASMA RESPIRATORY DISEASE.

Authors:  Nicole A Dobbs; Adam N Odeh; Xiangle Sun; Jerry W Simecka
Journal:  Curr Trends Immunol       Date:  2009

8.  Interleukin-17A Exacerbates Disease Severity in BALB/c Mice Susceptible to Lung Infection with Mycoplasma pulmonis.

Authors:  Maximillion T Mize; Xiangle L Sun; Jerry W Simecka
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

9.  Toll-like receptor 2 (TLR2) plays a major role in innate resistance in the lung against murine Mycoplasma.

Authors:  Wees Love; Nicole Dobbs; Leslie Tabor; Jerry W Simecka
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

10.  NK cells interfere with the generation of resistance against mycoplasma respiratory infection following nasal-pulmonary immunization.

Authors:  Sheetal Bodhankar; Mathew D Woolard; Xiangle Sun; Jerry W Simecka
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.